Adult-bCPAP: Treatment of COVID-19 Positive/Negative Bangladeshi Adults With Severe Respiratory Complaints by a Locally Made bCPAP: Feasibility Study

Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh (Other)
Overall Status
Completed
CT.gov ID
NCT05158842
Collaborator
Dhaka Medical College (Other), University of Edinburgh (Other)
20
2
1
4.3
10
2.3

Study Details

Study Description

Brief Summary

Low and middle-income countries (LMICs) urgently need cost-effective adaptive technologies to provide CPAP. The lead investigator has designed a device that has already been approved by the Directorate General of Drug Administration (DGDA), Government of the People's Republic of Bangladesh.

The design of the nasal seal was comfortable and well tolerated by all the participants. Patients were told about some mild discomfort at higher delivered pressures (14 or 15 cm PEEP), consistent with pressurised nasal delivery by similar devices.

The safety phase has been initiated since 1st November 2020 and ended in April 2021. One patient withdrew from the study but none of them developed any adverse events.

The feasibility phase started at the end of September 2021.

Objectives:
  1. To evaluate the barriers and operational challenges related to the introduction of adult bubble CPAP oxygen therapy

  2. To evaluate the acceptability of introducing adult bubble CPAP in tertiary level hospitals of Bangladesh

Condition or Disease Intervention/Treatment Phase
  • Device: Adult bubble CPAP oxygen therapy device
N/A

Detailed Description

Low and middle-income countries (LMICs) urgently need cost-effective adaptive technologies to provide CPAP. The lead investigator has proved that a low cost, locally made bCPAP device is capable of reducing mortality in children, Its components are (a) an interface; nasal seal, (b) oxygen delivery piping, connectors and nasal cannula, (c) appropriately sized transparent plastic bottles (containing sterilized water). The device and its components are already being approved by the Directorate General of Drug Administration (DGDA), Government of the People's Republic of Bangladesh. Adapting this technology, if safe and scaled up, could possibly decrease the need for mechanical ventilation and subsequently averting deaths among adult COVID-19 patients.

The design of the nasal seal was comfortable and well tolerated by all the participants. Patients were told about some mild discomfort at higher delivered pressures (14 or 15 cm PEEP), consistent with pressurised nasal delivery by similar devices. No additional adverse events such as trauma/injury, erosion, bruise, bleeding, obstruction, breathlessness, pneumothorax, pneumomediastinum, abdominal distension during and after the trial were reported.

The safety phase has been initiated since 1st November 2020 and ended in April 2021. One patient withdrew from the study but none of them developed any adverse events.

The feasibility phase started at the end of September 2021.

Objectives:
  1. To evaluate the barriers and operational challenges related to the introduction of adult bubble CPAP oxygen therapy

  2. To evaluate the acceptability of introducing adult bubble CPAP in tertiary level hospitals of Bangladesh

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Optimising the Treatment of COVID-19 Positive/Negative Adults With Severe Pneumonia and/or ARDS in Bangladesh Using an Adaptive Version of Locally Made Bubble CPAP: Feasibility Study
Actual Study Start Date :
Oct 8, 2021
Actual Primary Completion Date :
Feb 17, 2022
Actual Study Completion Date :
Feb 17, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Bubble CPAP Oxygen Therapy

Feasibility of Device

Device: Adult bubble CPAP oxygen therapy device
In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient. The components are: Adaptive version of nasal canula (nasal seal) A nasal canula with connecting circuit system Water-filled bottle with marking water pressure from10 to15 L/min. Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source.

Outcome Measures

Primary Outcome Measures

  1. Optimising the treatment of COVID-19 positive/negative adults with severe pneumonia and/or ARDS in Bangladesh using an adaptive version of locally made Bubble CPAP: Feasibility study [17 weeks]

    Barriers and operational challenges related to the introduction of adult bubble CPAP oxygen therapy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

INCLUSION CRITERIA

Adults for assessment:
  • Male or female

  • RT-PCR positive or negative for COVID-19

  • Aged 18-64 years, with severe pneumonia and hypoxemia (SpO2 < 90%).

  • Willing and able to provide written informed consent.

Staff:
  • Staff (physicians and nurses) who are engaged in the medicine ward, HDU and COVID ward of Dhaka Hospital of icddr,b and Dhaka Medical College Hospital.

  • Staff who agree to participate and give written informed consent.

EXCLUSION CRITERIA

Adults for assessment:
  • Patients will not be included in the study if they will not have adequate respiratory drive such as gasping respiration or requiring cardiopulmonary resuscitation or

  • Known to have life threatening heart disease,

  • Status asthmaticus

  • Upper-airway obstruction

  • Patients with pneumonia/respiratory tract illness but without hypoxaemia or SpO2< 80% in room air even on prone position and chest physiotherapy

  • Pregnancy, nasal polyp and

  • Patients who are not willing or able to provide written informed consent.

  • Arterial blood gas analysis will be performed to check the exclusion criteria.

Staff:

• For Focus Group Discussions, physicians and nurses who do not provide written informed consent will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dhaka Hospital, ICDDR,B Dhaka Bangladesh 1212
2 Dhaka Medical College Hospital Dhaka Bangladesh

Sponsors and Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh
  • Dhaka Medical College
  • University of Edinburgh

Investigators

  • Principal Investigator: Mohammod J Chisti, International Centre for Diarrhoeal Disease Research, Bangladesh

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
International Centre for Diarrhoeal Disease Research, Bangladesh
ClinicalTrials.gov Identifier:
NCT05158842
Other Study ID Numbers:
  • PR-20065
First Posted:
Dec 15, 2021
Last Update Posted:
Aug 25, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by International Centre for Diarrhoeal Disease Research, Bangladesh
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2022